The rise in cardiovascular disease prevalence, aging populations, and technological advancements in the field drive increased demand for interventional cardiology devices. As the industry prepares for ...

Background: The rate of in-stent restenosis (ISR) in clinical practice is approximately 5-10% after 5 years of percutaneous coronary intervention for coronary artery disease. ISR is associated with a ...

The global Implantable Drug Eluting Devices Market is poised for substantial growth, projected to expand at a compound annual growth rate (CAGR) of 6.0% from 2022 to 2029. The market, valued at ...

Endoscopy; Urology and Pelvic Health; and Neuromodulation. The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston ...

PORTLAND, GA, UNITED STATES, November 20, 2024 /EINPresswire / -- The global angioplasty balloons market size was valued at $2.6 billion in 2023, and is projected to reach $3.6 billion by 2033, ...

The AP is solely responsible for all content. Boston Police official says Mass and Cass spillover driving spike in violence, drug use downtown, on Common ...

Future Cardiol. 2009;5(2):141-157. Safety data for complex lesions with PES use led to the double-blind, multicenter TAXUS VI study. [33] This study included 444 patients with long and complex ...

Stent selection and concomitant antithrombotic strategies are the key considerations when finding the best balance between these opposite threats. Drug-eluting stents should be avoided or strictly ...

Background: Drug-coated balloons (DCB) have emerged as an effective treatment for in-stent restenosis and small vessel disease. DCB angioplasty might improve outcomes in heavily calcified lesions, a ...